Bayer doubles down on radiotherapy with acquisitions of 2 tiny biotech players built around research from Cornell
With #ASCO21 just days away, Swiss drugmaker Novartis is set to unveil late-stage data for its highly touted radioligand, potentially charting a new course for the once-disregarded field. Now, Bayer is looking to chase its own slice of the pie, signing its name to an early-stage pact based on science out of Cornell.
Bayer will pay an undisclosed sum to snatch up Noria Therapeutics and PSMA Therapeutics, two tiny biotechs built around radiotherapy research from the Weill Cornell Medical College in NYC, to expand its radiopharmaceutical pipeline, the German giant said Thursday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.